Luminex (NASDAQ:LMNX) Stock Rating Upgraded by BidaskClub

Luminex (NASDAQ:LMNX) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Monday, BidAskClub reports.

Separately, ValuEngine downgraded Luminex from a “buy” rating to a “hold” rating in a research note on Friday, May 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $23.33.

LMNX stock opened at $30.13 on Monday. The company has a market cap of $1.40 billion, a PE ratio of -200.85 and a beta of 0.67. The business has a 50-day simple moving average of $30.93 and a 200 day simple moving average of $27.35. Luminex has a 52 week low of $17.34 and a 52 week high of $40.21. The company has a quick ratio of 2.40, a current ratio of 4.00 and a debt-to-equity ratio of 0.04.

Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, May 4th. The medical instruments supplier reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. The business had revenue of $90.40 million during the quarter, compared to the consensus estimate of $82.30 million. Luminex had a negative return on equity of 1.25% and a negative net margin of 1.81%. Luminex’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.07 earnings per share. On average, analysts anticipate that Luminex will post 0.17 EPS for the current fiscal year.

In other Luminex news, SVP Randall Myers sold 75,000 shares of Luminex stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $31.05, for a total value of $2,328,750.00. Following the transaction, the senior vice president now owns 42,929 shares in the company, valued at $1,332,945.45. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director G Walter Loewenbaum II sold 86,657 shares of Luminex stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $31.27, for a total value of $2,709,764.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 296,254 shares of company stock worth $9,133,039. Company insiders own 9.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC grew its holdings in shares of Luminex by 22.9% during the first quarter. Mutual of America Capital Management LLC now owns 1,844 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 344 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of Luminex by 3.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,180 shares of the medical instruments supplier’s stock worth $308,000 after purchasing an additional 403 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Luminex by 16.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,857 shares of the medical instruments supplier’s stock worth $78,000 after purchasing an additional 406 shares during the last quarter. Prudential Financial Inc. grew its holdings in shares of Luminex by 1.0% during the fourth quarter. Prudential Financial Inc. now owns 66,267 shares of the medical instruments supplier’s stock worth $1,535,000 after purchasing an additional 634 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Luminex by 30.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,163 shares of the medical instruments supplier’s stock worth $87,000 after purchasing an additional 747 shares during the last quarter. Institutional investors own 80.71% of the company’s stock.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Featured Story: Are sell-side analysts objective?

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.